Drug Profile
Research programme: Alzheimer's disease vaccines - Merck
Latest Information Update: 31 Mar 2010
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Alzheimer vaccines
- Mechanism of Action Immunostimulants; Natural killer T cell modulators; Toll-like receptor 9 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 01 Jan 2008 Coley Pharmaceutical Group has been acquired by Pfizer
- 16 Apr 2007 Preclinical trials in Alzheimer's disease in USA (Parenteral)